Health and Health Commission issued a letter: prohibit the volume of procurement monopoly.

On July 15, the Shanghai Health and Care Commission and the Chinese Medicine Administration issued the Shanghai Key Action Plan for Deepening Medical Reform (2020-2022), which provides planning for the management of consumables and the centralized procurement model.
The following focus of the
Cypress blue instrument combing the following key points: ▍ change point 1: supplies centralized procurement scope will be expanded, public hospital operation of the new mechanism notice pointed out that by 2022, the supply side of pharmaceutical services reform has made substantial progress, drug supplies centralized procurement scope further expanded, public hospital operation compensation mechanism further optimized, improve the medical prevention coordination mechanism, the total budget framework of the "four-in-one" (DRG, big data,
▍ change point 2 : Primary health care will focus on, the medical union spread the notice that the primary level focus, prevention-oriented, prevention and combination;
▍ change point 3: health insurance, medical, medical linkage, the use of consumables price space in the future will continue to adhere to the three medical linkage.
promote the integration of health insurance, medical and pharmaceutical joint reform systems, strengthen policy and management coordination, make use of the space for price reduction after centralized procurement of pharmaceutical supplies, improve the dynamic adjustment mechanism of medical service prices, optimize the performance compensation system of public hospitals, and improve the public welfare operation mechanism of public medical institutions.
▍ change point 4 : New medical institutions, emergency notification pointed out: will improve the major public health emergency management mechanism.
speed up the standardization, standardization, homogenization management and equipment standardization of infectious disease source detection, and build a three-level infectious disease treatment system covering comprehensive medical institutions (including Chinese medicine medical institutions) and specialized medical institutions such as pediatrics, obstetrics and gynecology, and psychiatry.
improve the mechanism of guarantee for medical treatment and treatment of major outbreaks, and ensure that medical institutions pay for medical treatment and charges after the outbreak.
▍ change point 5: Tape procurement will be reformed, quality will be the key notice that will deepen the drug concentration of the volume procurement reform.
to undertake the daily work of the Joint State Procurement Office, take the lead in implementing the results of the national organization's centralized procurement of medicines and supporting measures, and play a role as a model leader.
to retain the balance of medical insurance funds for centralized imported procurement varieties, and further enhance the enthusiasm of medical institutions and medical personnel to participate in the reform.
speed up the construction of information-based traceability system, the implementation of the winning varieties of the whole process traceability, to achieve production, circulation, use of the whole cycle of quality supervision.
▍ change point 6 : There will be a bargain procurement pilot, the failure of the winning bid also has the opportunity to plan the point that will encourage and promote the drug centralized bargaining procurement pilot.
encourage public medical institutions to carry out centralized bargaining procurement of drugs that are not included in centralized volume procurement, such as medical unions, single bodies or voluntary procurement alliances, as an effective supplement to centralized band procurement, and to improve the scale effect of the bargaining on the internet.
▍ Change Point 7 : Encourage third parties to participate in procurement, prevent monopoly planning, the establishment of a sound incentive mechanism, centralized bargaining procurement of drugs pilot medical insurance fund balance retention, medical institutions to participate and implementation into the performance appraisal.
strengthen supervision and management, adhere to the procurement of sunshine, to ensure that patients, to ensure quality and supply.
encourage and regulate the participation of third-party drug centralized procurement organizations, prevent monopolies and form fair competition industry norms.
▍ change point 8: reduce the price of high-value consumables, increase sampling and steadily promote high-value medical supplies centralized procurement.
adhere to the principle of "quantity-for-price, classified procurement, comprehensive bidding, payment synergy, three-medical linkage", small incision, touch the path, on the basis of the pilot to steadily promote high-value medical supplies centralized procurement.
pay attention to meet the clinical reasonable needs, play the role of market mechanism, transparent workflow rules, and effectively reduce the high value of medical supplies false high prices.
establish and improve the incentive and supervision mechanism, coordinate and promote the standard of medical insurance payment, pay according to disease, medical service project price management, etc.;
▍ change point 9: Establish a price, credit evaluation system to establish a pharmaceutical price and credit evaluation system.
relying on the medical procurement sunshine platform, implement the national requirements, system integration and trustworthiness commitment, credit rating, graded disposal, credit repair and other mechanisms, establish the right and responsibility of reciprocity, coordination of linked pharmaceutical prices and tender procurement credit evaluation system, promote the honesty and trustworthiness of all parties, and jointly create a fair and standardized, clean circulation order and trading environment, and effectively protect the interests of the masses and the safety of the medical insurance fund.
▍ change point 10: high-value consumables catalog management, strictly prohibit the department procurement to improve the use of pharmaceutical supplies supervision.
increase the use of consumables governance, to ensure results.
strengthen the management and regulation of drug catalogues in medical institutions, promote medical institutions to adjust and optimize drug catalogues in a timely manner, and comprehensively establish a key drug monitoring mechanism by the end of December 2020.
regulate and strengthen the management of pharmaceutical products.
will be the unit price and resource consumption ratio of high-value medical supplies as the focus of governance objects, consolidate the high-value medical supplies special governance reform results, standardize high-value medical supplies catalog management, strengthen the operation management involving high-value medical supplies, establish high-value medical supplies hospital access selection mechanism, strictly prohibit the department self-procurement.
▍ change point 11 : Improve the price of medical devices, new devices should be put into clinical application as soon as possible to improve the new medical service items and can be charged medical device price management.
improve the collective review system for new project prices.
establish standardized and standardized review procedures and pricing rules to enhance the efficiency of collective deliberations.
improve the expert evaluation system of new projects and the evaluation system of health economics, and further improve the scientific and normative pricing.
improve the dynamic adjustment mechanism of the catalogue of medical devices that can be charged at an additional cost, and promote the introduction of new technologies and devices in medical services into clinical application as soon as possible.
research and establish a classification access system for medical service projects, explore the establishment of pricing mechanisms in line with market laws for innovative and breakthrough new projects, and give full play to the enthusiasm of medical institutions and medical personnel.
▍ change point 12: Implement the DRG payment pilot, expand the scope of the pilot to deepen the reform of the payment method of health insurance.
steadily implement the big data disease sub-payment and pay-per-view pilot, and expand the scope of the pilot in an orderly manner.
to 2022, on the basis of the city's pilot, to achieve the total budget framework of the "four-in-one" (DRG, big data diseases, bed-by-bed pay, by head bag dry) multi-composite health insurance payment model.
promote the multi-value payment system for big data diseases with regional medical centers as the core, improve the efficiency of the use of high-quality medical resources in tertiary hospitals as the core OF the DRG payment system, strengthen the family doctor contract service system as the core of the medical union pay-per-person system, establish a long-term hospital-based hospital-based pay-per-day system in line with the characteristics of mental rehabilitation care as the core, explore some of the Chinese and Western medical diagnosis clear, consistent with the evaluation of the efficacy of Chinese medicine multi-complex payment system.
reasonable determination, dynamic adjustment of the total budget indicators of the medical insurance fund and payment standards by disease.
improve the mechanism of collective consultation between the medical insurance sector and medical institutions.
original title: Health and Health Commission issued a letter: prohibit the volume of procurement monopoly, the introduction of supplies catalog.